Skip to main content
. 2023 Mar 7;12:28. doi: 10.1186/s40164-023-00381-7

Table 2.

Correlation between CDC20 expression and clinical features in 51 MCL patients

Clinical features Cases, N CDC20 expression χ2 P value
Low, n (%) High, n (%)
Total 51 21 (41.2) 30 (58.8)
Age
 <60 21 9 (42.9) 12 (57.1) 0.042 0.838
  ≥ 60 30 12 (40.0) 18 (60.0)
Gender
 Male 39 15 (38.5) 24 (61.5) 0.140 0.708
 Female 12 6 (50.0) 6 (50.0)
B symptoms
 Yes 24 8 (33.3) 16 (66.7) 1.151 0.283
 No 27 13 (48.1) 14 (51.9)
Pathological type
 Indolent 9 5 (55.6) 4 (44.4) 0.351 0.553
 Aggressive 42 16 (38.1) 26 (61.9)
ECOG
 <2 45 20 (44.4) 25 (55.6) 0.735 0.391
  ≥ 2 6 1 (16.7) 5 (83.3)
Ki-67
 <30% 19 12 (63.2) 7 (36.8) 6.041 0.014*
  ≥ 30% 32 9 (28.1) 23 (71.9)
WBC
 <10*10^9/L 34 13 (38.2) 21 (61.8) 0.364 0.546
  ≥ 10*10^9/L 17 8 (47.1) 9 (52.9)
β2-MG
 <3 mg/L 21 11 (52.4) 10 (47.6) 1.850 0.174
  ≥ 3 mg/L 30 10 (33.3) 20 (66.7)
LDH
 <240 IU/L 30 17 (56.7) 13 (43.3) 7.217 0.007**
  ≥ 240 IU/L 21 4 (19.0) 17 (81.0)
Stage
 I-II 11 8 (72.7) 3 (27.3) 4.223 0.040*
 III-IV 40 13 (32.5) 27 (67.5)
MIPI
 Low risk 20 13 (65.0) 7 (35.0) 9.743 0.008**
 Intermediate risk 12 5 (41.7) 7 (58.3)
 High risk 19 3 (15.8) 16 (84.2)
Involved lymph node areas
 <3 16 10 (62.5) 6 (37.5) 4.377 0.036*
  ≥ 3 35 11 (31.4) 24 (68.6)
BM involvement
 Yes 41 13 (31.7) 28 (68.3) 5.875 0.015*
 No 10 8 (80.0) 2 (20.0)
Treatment response
 CR/PR 31 18 (58.1) 13(41.9) 9.308 0.002**
 SD/PD 20 3 (15.0) 17 (85.0)

ECOG Eastern Cooperative Oncology Group, WBC white blood cell, LDH lactate dehydrogenase, β2-MG β2-microglobulin, MIPI MCL International Prognostic Index, BM bone marrow, CR complete remission, PR partial remission, SD stable disease, PD progressive disease

Bold values meant *P < 0.05 or **P <0.01.